PFAS Accountability Act of 2025
- Bill Number
- H.R. 6626
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Environmental Protection
- Status
- Introduced
- Latest Action
- 2025-12-11: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-01-31T09:05:30Z
AI-Generated Summary
Purpose of the Legislation
The PFAS Accountability Act of 2025 aims to address health risks from per- and polyfluoroalkyl substances (PFAS), a group of human-made chemicals used in manufacturing that persist in the environment and human body. It seeks to promote research on PFAS safety, hold manufacturers accountable for irresponsible practices, and provide affected individuals with federal legal options to seek remedies, including medical monitoring for potential health issues.
Key Provisions
- Findings: Recognizes widespread PFAS contamination in U.S. blood and drinking water (affecting over 200 million people), limited safety research on new PFAS, absence of a federal lawsuit option for exposure harms, and links to serious health problems like cancer, reproductive issues, and immune system damage.
- Federal Cause of Action: Adds a new section (Section 25) to the Toxic Substances Control Act (TSCA), allowing individuals "significantly exposed" to PFAS—or those with reasonable suspicion of such exposure—to sue in federal court. Suits can be individual or class actions against manufacturers involved in PFAS production (including related processes like telomer or fluorosurfactant manufacturing) if they foresaw or should have foreseen human exposure. Remedies include legal (e.g., damages) and equitable relief (e.g., court orders to stop practices).
- Medical Monitoring Remedy: Courts can order defendants to pay for ongoing medical tests if plaintiffs prove:
- Significant PFAS exposure.
- Increased risk of PFAS-related diseases.
- Need for extra or different diagnostic exams beyond routine care.
- Exams that effectively detect PFAS-linked diseases.
- Presumption of Significant Exposure: To ease proof for plaintiffs:
- Applies if PFAS from the defendant were released in areas where the person (or class) was exposed for at least one cumulative year, or if blood/body tests show PFAS presence.
- For class actions, proof can apply to a representative group with similar exposure.
- Rebutting the Presumption: Defendants can challenge exposure claims with independent testing (using accepted methods) showing PFAS levels were too low to qualify as significant; defendants cover testing costs, and courts appoint testers if parties disagree.
- Handling Limited Research: If toxicological data is insufficient to prove disease risk, courts can lower the scientific proof standard and order new studies (e.g., epidemiological or toxicological) as part of remedies to build reliable data.
- Sense of Congress: Encourages courts to support independent research on PFAS health effects.
- Non-Preemption: Explicitly preserves state laws and remedies; this federal option does not replace or limit them.
Significant Changes to Existing Law
- Introduces the first federal statutory right to sue for PFAS exposure harms under TSCA, filling a gap where no such nationwide cause of action existed before.
- Codifies "significant exposure" and related harms as legally recognized injuries, shifting medical monitoring costs from individuals to responsible parties.
- Allows courts to mandate research studies in cases, a novel tool to address data gaps not previously available in TSCA.
- Provides presumptions and cost-shifting to favor plaintiffs, reducing barriers to lawsuits compared to general tort law (personal injury claims).
Potential Impacts
- On Citizens: Empowers exposed individuals (e.g., those near contaminated sites or using PFAS products) to access federal courts for remedies, potentially covering lifelong medical checks and easing financial burdens from health risks without needing full proof of disease onset.
- On Government Agencies: May indirectly burden agencies like the Environmental Protection Agency (EPA) or Centers for Disease Control and Prevention (CDC) if courts order studies requiring federal input, but primarily shifts responsibility to private parties; no direct new mandates on agencies.
- On International Relations: Minimal direct impact, though it could influence global chemical safety standards by pressuring U.S. manufacturers (many with international supply chains) to invest in safer alternatives, potentially affecting trade in PFAS-related goods.
- Broader Effects: Increases litigation against PFAS producers, incentivizing industry to fund safety research to avoid suits; may accelerate cleanup or phase-out of risky PFAS uses.
Main Stakeholders Affected
- Individuals and Communities: Those exposed to PFAS through water, air, or products, gaining new legal tools for accountability and health support.
- PFAS Manufacturers and Users: Chemical companies involved in production or processes, facing heightened liability, lawsuits, and costs for testing or studies; incentivized to prioritize safer practices.
- Healthcare Providers and Researchers: Benefit from potential court-ordered studies and medical monitoring funds, aiding PFAS health research.
- Courts and Legal System: Handle more specialized cases, with tools like presumptions to streamline proceedings.
- Environmental and Public Health Groups: Supportive, as it advances accountability without overriding state efforts.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens federal environmental tort law by recognizing latent (future) harms like increased disease risk as actionable, without requiring current symptoms; preserves state sovereignty by avoiding preemption, allowing varied local responses. The presumption and lowered proof standards may face challenges for fairness but aim to counter industry advantages in scientific evidence.
- Constitutional: Aligns with due process by providing clear exposure definitions and rebuttal rights; no apparent conflicts with commerce clause (regulating interstate chemical trade) or takings clause, as it targets irresponsible actors rather than broadly restricting property.
- Political: Bipartisan potential in addressing public health crises (e.g., contaminated water), but could spark debates on industry regulation versus litigation burdens; promotes accountability amid growing PFAS scrutiny, signaling congressional intent to treat these "forever chemicals" as a priority without new regulatory agencies.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (4)
Rep. Dingell, Debbie [D-MI-6], Rep. Nadler, Jerrold [D-NY-12], Rep. Tlaib, Rashida [D-MI-12], Rep. Evans, Dwight [D-PA-3]
Recent Actions
- 2025-12-11: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-12-11: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-12-11: Introduced in House
- 2025-12-11: Introduced in House
Bill Versions
- PFAS Accountability Act of 2025 — issued 2025-12-11 — PDF (10 pages)